β Home
βΉοΈ Info
π§Ύ At a Glance π Core Facts ποΈ Products/Services β Ratings π§βπΌ Executives π¬ My Commentsπ‘ Analytics
π Insights π’ Company Q&A (574) π οΈ Industry Q&A (121) π Competitors π Price Low π Price Swings β‘ SWOT ποΈ PEST π Porter's Five Forces β¨ Score Positive β οΈ Risk Assessment π§© Segmentation π Ά Google Linksπ Ratios
π° Margins π Financial Ratios π± Growth π Enterprise Value π Key Metrics π΅ Dividendsπ§ Tools
β Due Diligenceπ§© Revenue Segmentation by Product
Switch to Location
| Fiscal year | Segment | Value |
|---|---|---|
| 2025 | Sotyktu | 291M |
| 2025 | Breyanzi | 1.36B |
| 2025 | Sprycel | 493M |
| 2025 | Eliquis | 14.44B |
| 2025 | Opdivo Ovantig | 238M |
| 2025 | Pomalyst/Imnovid | 2.73B |
| 2025 | Zeposia | 577M |
| 2025 | Abecma | 427M |
| 2025 | Reblozyl | 2.33B |
π° Explore more revenue segmentation data for Bristol Myers Squibb!
Sign up for free or log inπ Join us and grab your copy of "The Checklist Value Investor β A Smarter Way to Pick Stocks"